Noubar Afeyan, Director at Moderna, Inc. (MRNA), sold 24,500 shares at $118.30 ($2.9M) on 2024-07-24, disclosed to the SEC on 2024-07-26.
Scheduled sale ($2.9M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $116.33 | 2,668 | $310K | 10.8% |
| 2 | $116.33 | 2,668 | $310K | 10.8% |
| 3 | $117.25 | 3,500 | $410K | 14.2% |
| 4 | $118.30 | 6,832 | $808K | 28.0% |
| 5 | $118.30 | 6,832 | $808K | 28.0% |
| 6 | $119.01 | 2,000 |
| $238K |
| 8.2% |
| Total | $117.78 avg | 24,500 | $2.9M | 100% |
| Filing → |
| MRNA | SELL | 2025-12-15 | $1.4M | — | Filing → |
| MRNA | SELL | 2024-08-02 | $3.6M | — | Filing → |
| MRNA | SELL | 2024-07-19 | $3.0M | — | Filing → |